Oppenheimer assumed coverage on shares of Recro Pharma (NASDAQ:REPH) in a research report issued on Tuesday. The firm set an “outperform” rating and a $19.00 price target on the specialty pharmaceutical company’s stock. Oppenheimer’s target price points to a potential upside of 131.43% from the company’s previous close.

Several other brokerages also recently commented on REPH. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $12.88.

Recro Pharma (NASDAQ:REPH) opened at $8.21 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $10.59.

In other news, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of Recro Pharma stock in a transaction on Friday, December 29th. The shares were sold at an average price of $9.27, for a total transaction of $169,001.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $9.58, for a total transaction of $2,132,661.28. The disclosure for this sale can be found here. Insiders have sold a total of 860,414 shares of company stock valued at $8,289,916 over the last ninety days. 21.60% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of REPH. Schwab Charles Investment Management Inc. bought a new stake in shares of Recro Pharma during the 2nd quarter worth $215,000. Bank of New York Mellon Corp lifted its holdings in shares of Recro Pharma by 182.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,532 shares of the specialty pharmaceutical company’s stock worth $355,000 after acquiring an additional 32,655 shares during the last quarter. Teachers Advisors LLC bought a new stake in shares of Recro Pharma during the 2nd quarter worth $162,000. TIAA CREF Investment Management LLC bought a new stake in shares of Recro Pharma during the 2nd quarter worth $249,000. Finally, Northern Trust Corp lifted its holdings in shares of Recro Pharma by 428.5% during the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after acquiring an additional 144,676 shares during the last quarter. 61.88% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Recro Pharma (REPH) Receives New Coverage from Analysts at Oppenheimer” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/13/oppenheimer-initiates-coverage-on-recro-pharma-reph.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.